trivalent inactivated influenza vaccine high dose

**Trivalent inactivated influenza vaccine high dose** is an egg-derived, split-virion seasonal influenza vaccine developed and manufactured by **Sanofi** and marketed as **Fluzone High-Dose**. It is indicated for active immunization against influenza caused by vaccine-contained influenza A and influenza B viruses in adults aged 65 years and older. Each 0.5 mL intramuscular dose contains 60 micrograms of hemagglutinin antigen from each of three influenza strains—A/H1N1, A/H3N2, and B/Victoria—representing four times the hemagglutinin antigen content of standard-dose inactivated influenza vaccines. The vaccine viruses are propagated in embryonated chicken eggs, inactivated with formaldehyde, and disrupted to form a split-virus preparation. Vaccination induces strain-specific humoral immune responses, including neutralizing antibodies directed principally against influenza hemagglutinin, to reduce the risk of influenza disease. It was initially approved in the United States in 2009 and is preferentially recommended by CDC and ACIP for adults aged 65 years and older when available.

Brand names

EflueldaFluzone High-Dose

Other names

high-dose trivalent inactivated influenza vaccinehigh-dose trivalent influenza vaccineinfluenza virus vaccine trivalent types A and B split viriontrivalent high-dose inactivated influenza vaccinetrivalent inactivated influenza vaccine high dose